08.25.25 -- Take Your Small Molecule Drug Development To The Next Level

Learn about UK-based Upperton Pharma Solutions, including their extensive expertise and capabilities across oral solids and specialized nasal and pulmonary formulations.

Reconstituted nasal epithelium (RNE) offers a human-relevant model for nasal drug delivery, outperforming frozen mucosa and aligning better with clinical outcomes for opioid formulations.

Millipore CTDMO Services supports small molecule API synthesis projects from milligram to commercial quantities. We are the partner to address the most difficult challenges.

Learn how a partner with comprehensive services can help you reduce development risks, shorten time to market, and navigate complex global regulations with ease.

Lonza's Route Scouting Service empowers biotech partners to overcome the complexities of API development and bring life-changing medicines to market faster.

We specialize in the custom development and manufacturing of small molecule APIs, intermediates, and RSMs, offering scalable solutions from kilograms to multi-ton quantities.

Ensuring critical OSD therapeutics reach patients successfully relies on the ability of developers and manufacturers to navigate the inherent issues surrounding their increasing complexity.

This research demonstrates the potential of high-pressure sterile filtration to enhance efficiency, reduce waste, and accelerate the development of innovative therapies.

At Quotient Sciences, we have supported more than 100 modified-release (MR) development programs over the past decade across a wide variety of therapeutic areas.

Dr. David Rowe, Head of Manufacturing at Nanoform, provides an overview of Nanoform's manufacturing capabilities and introduces a new, state-of-the-art nanotechnology facility.

Consumers appreciate the convenience sachets bring to their active lives and manufacturers understand that this convenience and dose accuracy lead to improved consumer compliance.

Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.

The Pharma Expanse network currently spans across 9 manufacturing sites in 5 countries and can support discovery, preclinical, clinical and commercial programs for NCEs.